L&G
BIOT.L
IE00BF0H7608
L&G Pharma Breakthrough UCITS ETF
Loading chart...

Analytics & Allocation

Detailed breakdown by growth drivers, valuation & quality, and asset allocation

Growth Drivers (Estimates)

Largest contributors to earnings and revenue growth

Balance Sheet & Financial Health

Aggregated leverage and valuation structure

Weighted P/E
16.94
Weighted Fwd P/E
20.5
Avg P/FCF
26.6
Avg FCF Yield
0.29%
Avg EV / EBITDA
47.14
Avg EV / Revenue
12.63
Avg Price-to-Book (P/B)
34.59
Avg Price-to-Sales (P/S)
7.4
Avg Dividend Yield
0.00%
P/E Compression (Trailing vs Fwd)
+21.05%
Avg Debt-to-Equity (D/E)
303.75%
<50% (39.37%) 50-150% (27.36%) >150% (14.11%) Unreported (19.16%)

Profitability Analysis

41 Holdings Count
Profitable 88.62%
Profitable 88.62%
36 Holdings Count (87.8%)
Unprofitable 11.38%
5 Holdings Count (12.2%)

ETF Concentration (Cumulative Weight)

Cumulative weight of positions (Lorenz curve)

Broadly Diversified
Top 5
13.5%
Top 10
26.5%
Top 25
63.7%
50% Threshold
Top 20
The top 10 make up only 26.5%. Very balanced distribution with minimal single-stock risk. The steeper the curve initially rises, the more the largest positions dominate the fund volume.

Geographic Distribution

13 Countries
Loading TopoJSON Map...
0% (No exposure)
Tiers:
Low (0.1%+)
Med (15.1%+)
High (39.2%+)
Top (54.3%+)

Country Breakdown

Max: 60.34%
US US US
60.34%
JP JP JP
10.07%
CH CH CH
5.31%
DK DK DK
2.63%
GB GB GB
2.61%
IT IT IT
2.58%
IE IE IE
2.48%
CN CN CN
2.43%
SE SE SE
2.38%
NL NL NL
2.36%
KR KR KR
2.29%
FR FR FR
2.29%
ES ES ES
2.23%

Sector Distribution

2 Sector
Healthcare
97.71%
Basic Materials
2.29%

Industry Distribution

4 Industries
Biotechnology
62.80%
Drug Manufacturers - Specialty & Generic
19.68%
Drug Manufacturers - General
15.23%
Chemicals
2.29%

Market Cap Distribution

41 Holdings Count
Mega Cap (> 200B)
(3) 7.53%
Large Cap (10B - 200B)
(17) 42.00%
Mid Cap (2B - 10B)
(9) 21.48%
Small / Micro Cap (< 2B)
(12) 28.99%
ende